Seladelpar · Livdelzi
Small molecule
Also known as MBX-8025
Evidence outlook
Approved: Primary Biliary Cholangitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- LYVDELZI (seladelpar) is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. Marketing authorization with conditions for this indication is based on a randomized, placebo-controlled, phase III study that assessed alkaline phosphatase (ALP) and bilirubin as a composite biochemical surrogate endpoint [see 14 CLINICAL TRIALS]. Continued approval for this indication is contingent upon verification of clinical benefit in a...
- Primary biliary cholangitis (PBC) with UDCA in adults with an inadequate response to UDCA, or as monotherapy in those unable to tolerate UDCA (Lyvdelzi, conditional)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04620733 NCT04620733 · Primary Biliary Cholangitis This randomized, double-blind, placebo-controlled Phase 3 trial enrolled 193 adults with primary biliary cholangitis who had an inadequate response to, or could not tolerate, ursodeoxycholic acid. The primary endpoint was a composite biochemical response at Month 12 based on alkaline phosphatase and bilirubin, a laboratory measure that stands in for long-term liver outcomes. It was met: 61.7% of seladelpar participants responded versus 20.0% on placebo (risk difference 41.7 percentage points, 95% CI 27.7 to 53.4, p<0.0001). The record reports no power calculation or planned enrolment. Registry: NCT04620733 | 3 | Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12; Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (First dose date up to last dose plus 30 days (up to 13.4 months)); Percentage of Participants With Shift of ≥ 2 CTCAE Grades From Baseline in Treatment-emergent Laboratory Abnormalities Related to Hematology and Select Liver Biochemistry (First dose date up to last dose (up to 13.4 months)) 2023-08-11 | Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results). | Partial signal | link ↗ |
View 2 more trials
NCT03602560 NCT03602560 · Primary Biliary Cholangitis This randomized, double-blind, placebo-controlled Phase 3 trial tested seladelpar 10 mg or 5 to 10 mg against placebo in patients with primary biliary cholangitis who had an inadequate response to or intolerance of ursodeoxycholic acid. At Month 3, the composite biochemical response (alkaline phosphatase and bilirubin criteria) was reached by 43 of 55 patients on 10 mg and 32 of 56 on 5 to 10 mg, against 7 of 56 on placebo (p<0.0001 for each comparison). Only 167 of the 265 enrolled patients were in the analysis set, and the record reported no power calculation or planned enrolment, so adequate power could not be confirmed. Registry: NCT03602560 | 3 | Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3 2020-02-16 | Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3 (Month 3): Seladelpar 5-10 mg 32 Participants | Seladelpar 10 mg 43 Participants | Placebo 7 Participants | Partial signal | link ↗ |
IDEAL NCT06060665 · Primary Biliary Cholangitis This was a randomized, double-blind Phase 3 trial with 96 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-06-02. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate. Registry: NCT06060665 | 3 | Percentage of Participants Response defined as Alkaline phosphatase (ALP) ≤ 1.0× Upper Limit of Normal (ULN) AND ≥ 15% Decrease in ALP at Week 52 (52 weeks); Type, Frequency, and Severity of Treatment-emergent Adverse Events (52 weeks) 2026-05-06 | Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Primary Biliary Cholangitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Seladelpar (Livdelzi): this drug | Approved | Small molecule | PPAR-delta | Partial signal | NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02). NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results). | |
| Elafibranor (Iqirvo) | Approved | Small molecule | PPAR-alpha/PPAR-delta | Partial signal | NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8) | |
| Saroglitazar (Lipaglyn) | Phase 3 | Small molecule | PPAR-alpha/PPAR-gamma | Partial signal | NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29). | |
| Pemafibrate (Parmodia) | Phase 2 | Small molecule | PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Setanaxib | Phase 2 | Small molecule | NOX1/4 | not yet graded | No reviewed efficacy summary in this indication | |
| Volixibat | Phase 2 | Small molecule | Ileal bile acid transporter (IBAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Livdelzi (Seladelpar) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
2028 (2)
2030 (1)
August 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent